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We investigated the ability of a selection of human influenza A viruses, including recent clinical isolates, to induce IFN-h production in
cultured cell lines. In contrast to the well-characterized laboratory strain A/PR/8/34, several, but not all, recent isolates of H3N2 viruses resulted in
moderate IFN-h stimulation. Through the generation of recombinant viruses, we were able to show that this is not due to a loss of the ability of the
NS1 genes to suppress IFN-h induction; indeed, the NS1 genes behaved similarly with respect to their abilities to block dsRNA signaling.
Interestingly, replication of A/Sydney/5/97 virus was less susceptible to pre-treatment with IFN-a than the other viruses. In contrast to the
universal effect on dsRNA signaling, we noted differences in the effect of NS1 proteins on expression of interferon stimulated genes and also
genes induced by a distinct pathway. The majority of NS1 proteins blocked expression from both IFN-dependent and TNF-dependent promoters
by an apparent post-transcriptional mechanism. The NS1 gene of A/PR/8/34 NS1 did not confer these blocks. We noted striking differences in the
cellular localization of different influenza A virus NS1 proteins during infection, which might explain differences in biological activity.
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The innate immune response is the first barrier a virus
encounters after entry into the infected cell and is initiated
within hours of receptor binding. It involves the induction of
many factors, including the type I IFNs (IFNs-a/h) which
induce a range of antiviral processes. The complex mechanisms
of these processes are not fully elucidated. Within an infected
cell, it is believed that the proximal inducer of IFNs-a/h is
intracellular double-stranded RNA (dsRNA) generated as an
intermediate during viral replication. The dsRNA triggers a
series of events culminating in the activation of PKR and other
kinases (TBK-1 and IKK(). Phosphorylation of the substrates
of these enzymes results in the translocation of transcription
factors NF-nB and IRF-3 from the cytoplasm to the nucleus0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: w.s.barclay@reading.ac.uk (W. Barclay).where, together with factors ATF-2/c-Jun, IRF-7, p300 and
CBP, they bind to the IFN-h promoter to form a transcription
complex which ultimately drives IFN-h production (Wathelet
et al., 1998). Secreted IFN-h subsequently binds to its receptor
on the same cell or on neighbouring uninfected cells inducing
an antiviral state. This binding step initiates the activation of a
JAK/STAT pathway. Consequently, the Interferon Stimulated
Response Element (ISRE) in the promoters of many IFN
response genes are induced, and an array of genes, including
PKR, 2V,5V-oligoadenylate synthetases and Mx proteins, are
expressed (as reviewed by Goodbourn et al., 2000).
IFNs were first discovered as factors induced by treatment
of cells with heat inactivated influenza virus that could inhibit
viral replication (Isaacs and Lindenmann, 1957). Interestingly,
many negative strand RNA viruses, for example Sendai Virus,
Simian Virus 5 (Didcock et al., 1999a), Ebola Virus (Basler et
al., 2003) and human influenza A virus, possess mechanisms of
counteracting this host defense system. There is a body of
evidence suggesting that the non-structural protein 1 (NS1)06) 52 – 64
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antagonistic effect on the production of type I IFN. In the
context of virus infection, Garcia-Sastre and colleagues showed
in 1998 that a recombinant A/PR/8/34 strain lacking the NS1
gene, termed delNS1, was highly attenuated in IFN-competent
MDCK cells and 10-day-old chicken embryos. In contrast, the
delNS1 virus grew in IFN-deficient systems including Vero
cells, young chicken embryos and STAT1/ mice (Egorov et
al., 1998; Garcia-Sastre et al., 1998). The specific mechanisms
by which the NS1 protein confers the block in IFN-h
production are still not fully resolved. It has been suggested
that the NS1 protein might bind to and sequester dsRNA
produced during viral infection, thereby inhibiting the down-
stream events that lead to IFN-h induction. The NS1 protein
can bind to both single- and double-stranded RNA, however,
the affinity for dsRNA is higher (Hatada and Fukuda, 1992).
Amino acids in the amino terminus of NS1 are implicated in
this interaction (Qian et al., 1994). Substitution of basic amino
acids at position 38 and 41 showed that these two positions are
specifically required to mediate dsRNA binding. Structural
analyses imply that the arginine at position 38 binds
electrostatically to the dsRNA, and that the lysine at position
41 contributes to the affinity (Wang et al., 1999). NS1
expression constructs with mutations R38A and K41A were
no longer able to prevent the translocation of IRF-3 to the
nucleus (Talon et al., 2000) or the activation of NF-nB (Wang
et al., 2000). Furthermore, a recombinant WSN virus with the
same two mutations induced higher amounts of IFN-h in A549
cells than wild-type virus and was more attenuated in mice
(Donelan et al., 2003), thus supporting a role for a NS1-dsRNA
interaction in blocking IFN-h induction.
NS1 also binds two proteins involved with mRNA proces-
sing and transport, namely cleavage and polyadenylation
specificity factor (CPSF) and poly (A)-binding protein II
(PABII) (Chen et al., 1999; Nemeroff et al., 1998). Amino
acids 215 to 237 have been identified as the binding site for
PABII (Li et al., 2001). The CPSF binding site is located
around residue 186 (Li et al., 2001). Krug and colleagues have
proposed that this domain of NS1 can prevent the antiviral
response by inhibition of post-transcriptional processing of the
3V ends of cellular antiviral mRNAs (Noah et al., 2003). A
recombinant virus with mutations at positions 184 to188 was
attenuated in IFN competent cells and infection resulted in high
production of antiviral mRNAs (Noah et al., 2003). Consistent
with this, Ortı´n and colleagues had already shown that NS1
expression causes retention of mRNAs in the nucleus (Fortes et
al., 1994). Furthermore, incomplete processing of recently
induced mRNAs was observed in influenza A virus infected
cells and was deficient for a virus mutant with a temperature
sensitive defect mapping to the NS1 gene (Shimizu et al.,
1999).
Several studies have nevertheless demonstrated that NF-nB
and IFN-h mRNA are induced and upregulated respectively
upon influenza virus infection in dendritic cells, macrophages
and A549 cells, implying that blocks in IFN-h mRNA
induction are not complete (Huang et al., 2001; Matikainen
et al., 2000; Ronni et al., 1997). Infection with wild-typeinfluenza A virus (A/Udorn/72) resulted in both the activation
of IRF-3 (Kim et al., 2002) and the production of IFN-h
mRNA albeit at low levels (Noah et al., 2003). Moreover, the
downstream events of IFN signaling have also been detected
upon influenza virus infection. This implies that despite the
ability of the virus to block several stages of the IFN induction
pathway, all of the blocks to IFN induction are incomplete and
some IFN is secreted. MxA mRNA was detected by Northern
blot analysis in human lung cells (A549s and HFL1) and
PBMCs infected with wild-type (A/Beijing/353/89, H3N2)
influenza virus (Ronni et al., 1995, 1997), and microarray
analysis demonstrated that MxAwas upregulated in A549 cells
upon infection with both a wild-type A/PR/8/34 strain and the
del NS1 virus (Geiss et al., 2002; Ronni et al., 1997). mRNA
expression levels of MCP-1, MCP-3 and IP10 were also
enhanced in macrophages infected with virus (A/Beijing/353/
89) in an IFN-dependent manner (Geiss et al., 2002;
Matikainen et al., 2000). Notably, influenza virus induces
more IFN gene expression in macrophages than in A549 cells,
implying that the level of induction might also be cell type
dependant (Ronni et al., 1997).
In previously published studies, various different strains of
influenza virus have been used by different groups. These
strains contain sequence variation in their viral proteins,
including NS1, yet it is often assumed that their properties
are typical of all influenza viruses. However, strains which
have undergone extensive laboratory passage for more than 70
years, such as A/WSN/33 and A/PR/8/34, may not reflect the
characteristics of more recent isolates with a lower passage
history or clinical isolates. Indeed, it has been shown that
continuous passage in cell culture can lead to viruses which
have lost the ability to control IFN induction (Hagmaier et al.,
2003). In this study, we therefore wished to address whether
different human influenza viruses varied in their IFN-h
antagonistic properties. A panel of viruses, including labora-
tory-adapted strains and recent clinical isolates, was produced,
and the ability of each virus to induce and inhibit IFN-h
induction was investigated. We have found a great deal of
variation in the IFN-h induction profiles of different influenza
A strains, although there is no clear distinction between of
laboratory-adapted and non-laboratory-adapted strains. The
efficiency and mechanism by which the IFN response is
blocked are clearly strain-specific.
Results
Wild-type influenza strains vary in their induction of IFN-b and
their activation of cellular signaling pathways
To assess the ability of a panel of human influenza A viruses
(Table 1) to induce IFN-h, we generated a stable A549 human
lung alveolar cell line containing a firefly luciferase gene
driven by the IFN-h promoter. Cells were infected at an moi of
5, and induction of the reporter was assessed after 8 h (Fig.
1A). Most of the viruses were poor inducers of IFN-h promoter
activity. Unexpectedly, infection with a subset of the strains
tested, namely A/England/327/90, A/England/41/96 and A/
Table 1
Panel of viruses
Strain Subtype Passage history
Laboratory adapted:
A/PR/8/34 H1N1 Extensively passaged in eggs, mouse adapted
A/Victoria/3/75 H3N2 Laboratory adapted
A/Sydney/5/97 H3N2 Recent isolate, passaged in eggs
Antigenic property
Clinical isolate, passaged 3–4 in MDCKs:
A/England/492/95 H3N2 A/Johannesburg/33/94
A/England/41/96 H3N2 A/Johannesburg/33/94
A/England/919/99 H3N2 A/Sydney/5/97
A/England/24/00 H3N2 A/Panama/2007/99
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Western blot analysis showed that equivalent amounts of NP
and NS1 accumulated in cells infected by viruses regardless ofFig. 1. Influenza A virus strains induce different amounts of IFN-h promoter
activity. (A) An A549 IFN-hLuc reporter cell line was infected with a panel of
viruses at an moi of 5. Luciferase activity was measured 8 h post-infection. (B)
Western blotting was performed to compare the amount of NP and NS1
produced 8 h post-infection. (C) The A549 IFN-hLuc reporter cell line was
infected with a selection of viruses at an moi of 5 which had or had not been
UV inactivated. Luciferase activity was measured 8 h post-infection.the extent to which IFN-h had been induced (Fig. 1B). This
was also confirmed by biosynthetic labeling of polypeptides
with S35 (data not shown). IFN-h induction was abolished
upon UV inactivation of the virus, implying induction was
dependent on replication (Fig. 1C).
In order to establish that the IFN-h promoter induction
observed resulted in IFN-h synthesis and its secretion, we
measured the levels of endogenous IFN-h mRNA produced
during infection with a subset of the viruses (Fig. 2A) and the
amount of IFN-h secreted in the supernatant by ELISA (Fig.
2B). The profile was similar to that observed with the reporter
construct (Fig. 1A). Low levels of IFN-h were secreted by cells
infected with most of the influenza Aviruses, and infection with
A/Sydney/5/97 resulted in the highest IFN-h secretion into the
medium. We note that infection with A/Sydney/5/97 also leads
to the induction of the dsRNA- and IFN-responsive ISG56 (Fig.
2A) and ISG15 genes (data not shown).
Since induction of the IFN-h promoter is associated with
the activation of NF-nB and IRF-3, we next investigated the
status of these factors in infected cells. Following infection
with A/Sydney/5/97, NF-nB was detected in increased
amounts in the nuclear extracts of infected cells (Fig. 3A). A
minor amount was also detectable upon infection with A/PR/8/
34, A/Victoria/3/75 and A/England/492/95. To investigate the
state of activation of IRF-3, we examined the localization
during viral infection. This showed that IRF-3 was translo-
cated from the cytoplasm to the nucleus in many of the cells
infected by A/Sydney/5/97 (Fig. 3B). In contrast, infectionFig. 2. IFN-h is made and secreted from A549 cells upon influenza A virus
infection. (A) A549 cells were infected with virus at an moi of 5 for 2 h and
then treated with or without IFN-a 1000 IU/ml for a further 2 h. RNA was
extracted and probed for IFN-h or ISG56 mRNA. (B) A549 cells were infected
with viruses at an moi of 5. 24 h post-infection, the amount of IFN-h released
into the culture supernatant was measured by ELISA.
Fig. 3. Infection with influenza virus A/Sydney/5/97 results in increased amounts of NF-nB in the nucleus and the activation of IRF-3 in comparison to infection with
A/PR/8/34 or A/Victoria/3/75. (A) A549 cells were infected with virus at an moi of 5 for 4 h, nuclear extracts prepared and an EMSA carried out for NF-nB. (B)
A549 cells were infected with virus at an moi of 5 for 8 h and then strained for IRF-3 (green) and virus NP (red).
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tion of IRF-3.
A/Sydney/5/97 is less susceptible to pre-treatment of cells with
interferon than are other influenza A strains
Despite inducing IFN-h, A/Sydney/5/97 was still able to
undergo multiple cycles of replication in the A549 cells
(Fig. 4A). We therefore assessed whether A/Sydney/5/97
could replicate in cells previously treated for 24 h with IFN-
a. Treatment with IFN-a did not completely block multi-
cycle replication of any of the viruses tested (Fig. 4B);
however, A/Sydney/5/97 was less sensitive to the antiviral
effects of the exogenous IFN-a, compared with A/PR/8/34
and A/Victoria/3/75.
The NS1 proteins of a range of human influenza A viruses can
inhibit dsRNA stimulated IFN-b reporter induction
NS1 has been shown to play an important role in
modulating the host IFN-h response. We determined the
sequence of the NS1 proteins from each virus and noted
several amino acid changes (Table 2). We therefore wanted to
establish whether the differences observed in IFN-h induction
between the viruses were defined by differences in the
sequence of NS1 proteins. In particular, we wanted to test
whether the NS1 protein of A/Sydney/5/97 virus was ineffec-
tive at limiting IFN-h induction. We cloned and expressed theNS1 genes derived from representative viruses from the panel
and tested their ability to block dsRNA- or SeV-stimulated
IFN-h induction. All of the NS1 proteins blocked IFN-h
induction to similar extents in both A549 (Fig. 5A) and Vero
cells (Fig. 5B). No differences were observed between the
different NS1 constructs when compared across a wide range
of concentrations (data not shown). Equivalent amounts of NS1
protein were expressed, with the exception of A/PR/8/34 NS1,
which showed increased expression (Fig. 5C). We attribute the
increased expression of NS1 from A/PR/8/34 to the documen-
ted ability of this gene product to enhance translation of
proteins expressed from cDNA constructs (Salvatore et al.,
2002).
Recombinant influenza A viruses that differ only in their
segment 8 genes do not vary in their IFN-b induction in A549
cells
To confirm the observation that NS1 proteins from all the
influenza A virus strains in the panel were able to block IFN-
h induction, we also used reverse genetics to engineer viruses
with heterologous NS genes in a stable genetic background of
A/Victoria/3/75. As there were sequence changes in the
overlapping region encoding NS1 and NEP, the entire NS
gene (RNA segment 8) was exchanged. The cells were
infected with the recombinant viruses and IFN-h induction
measured after 8 h (Fig. 6A). Strikingly, the recombinant
virus with A/Sydney/5/97 NS gene or with A/England/41/96
Fig. 4. A/Sydney/5/97 virus is less susceptible to pre-treatment of cells with
interferon than other influenza A virus strains. (A) A549 cells were infected
with influenza A viruses at an moi of 0.01. Culture supernatants were then
harvested at 24, 48 and 72 h post-infection and titrated on MDCK cells. (B)
A549 cells were incubated with 1000 IU/ml IFN-a for 24 h. The cells were then
infected at an moi of 0.01. 48 h post-infection, cell culture supernatants were
titrated on MDCK cells.
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induced only low levels of IFN-h, similar to all the other
recombinant viruses. A Western blot analysis to quantify NS1
protein accumulation in cells infected with wild-type A/
Sydney/5/97 virus or with the recombinant A/Victoria/3/75
bearing the A/Sydney/5/97 NS gene indicated that very
similar levels of NP and NS1 were produced in comparison
to the other viruses (Figs. 1B and 6B). Thus, the high
induction of IFN-h by wild-type A/Sydney/5/97 virus was not
explained by a defect in NS1 sequence or NS1 protein
accumulation in infected cells.
NS1 effects on ISRE function
Although the A/Sydney/5/97 wild-type virus induced more
IFN-h production than the other viruses, it showed increased
resistance to the antiviral effects of the IFN-h it induced during
infection. We therefore investigated whether influenza A
viruses can block the consequences of IFN-h production by
inhibiting the IFN-h induced activation of genes under the
control of the ISRE (IFN-stimulated response element). A549
cells were transfected with a luciferase reporter construct
containing 4 repeats of an ISRE from the 9–27 promoter(ISRELuc), and then infected with wild-type virus at an MOI
of 5. Exogenous IFN-a was applied to induce the ISRE. All of
the viruses inhibited the signal in this assay, with the exception
of A/PR/8/34 (Fig. 7A). It is notable that all of the viruses
induced some luciferase, even in the absence of exogenous
IFN-a, probably because the initial block on IFN production is
not complete.
To confirm that the apparent block in ISRE induction was
conferred by the NS1 protein, cells were co-transfected with
the ISRE reporter construct and expression plasmids for each
of the NS1 proteins. 48 h post-transfection, cells were
incubated with IFN-a, and luciferase activity was measured.
Again all of the NS1 proteins, except A/PR/8/34 NS1,
blocked the ISRE induced signal in both A549 and Vero
cells (Figs. 7B and C). To verify the role of NS1 in the
context of viral infection, we also showed that the recombi-
nant virus containing the A/PR/8/34 NS gene in a genetic
background of A/Victoria/3/75 behaved like the wild-type
virus A/PR/8/34, i.e., neither virus blocked the ISRE induced
signal (Fig. 7D).
To investigate whether the block by NS1 to the IFN induced
expression from ISRE-luciferase was operating at the level of
signal induction, we looked at the formation of ISGF3 in the
nucleus of cells infected with A/PR/8/34 virus or with A/
Victoria/3/75. In both cases, the formation of ISGF3 was the
same as in interferon treated cells which had been mock
infected (Fig. 8A).
Although the results of the reporter assays would suggest
that the NS1 proteins typified by A/Victoria/3/75 were
blocking the signal transduction pathway leading to the
activation of the ISRE, the results in Fig. 8A suggested that
signaling was not affected. We were mindful of the
additional property of NS1 to block post-transcriptional
processing and considered that the block exerted by the
NS1 protein of A/Victoria/3/75 was mediated after the
production of the mRNA transcript. A block of this nature
should be effective against a range of transiently induced
genes. To test this, we assessed the abilities of the NS1
proteins to block expression of another promoter whose
activation pathway was unrelated to that of the ISRE. Each
NS1 protein affected the TNFa induction of an NF-nB-
dependent reporter (Fig. 8B) in the same way as had been
observed for induced expression from the ISRE luciferase
reporter. An analysis of the abilities of A/PR/8/34 and A/
Victoria/3/75 viruses to block NF-nB activation in response
to TNFa confirmed that the block was not operating on the
TNFa signal transduction pathway (Fig. 8C), since NF-nB
was present in nuclear extracts of treated cells, again
consistent with a post-transcriptional effect.
To address the genetic basis of the difference between
NS1 proteins of A/PR/8/34 and A/Victoria/3/75 in blocking
expression of newly induced genes, we engineered two
chimeric NS1 genes which contained either RNA binding
domains (amino termini) or effector domains (carboxy
termini) from each virus. The ability to block IFN-induced
ISRE gene expression mapped to the effector domain (Fig.
9A). Within this domain two regions have been described
Table 2
Amino acid changes in NS1
Position 3 18 21 22 23 26 27 28 41 48 55 56 59 60
Consensus S I Q V V E I S R N K A H V
A/PR/8/34 P V R – A – – G K S E T R A
A/Victoria/3/75 – V – I – – – G K S E – – –
A/Sydney/97 – – – – – – – – – – – – – –
A/England/492/95 – – – – – – – – – – – – – –
A/England/41/96 – – – – – – – – – – – – – –
A/England/919/99 – – – – – K – – – – – – – –
A/England/24/00 – – – – – – K – – – – – – –
Position 67 78 82 84 90 95 98 101 103 106 107 111
Consensus K K A T I I L N F M P V
A/PR/8/34 R – – V L L M D S I – –
A/Victoria/3/75 – T – – – T – D – – – –
A/Sydney/97 – – – – – – – – – – – –
A/England/492/95 – – – – – – – – – – – –
A/England/41/96 – – – – – – – – – – S –
A/England/919/99 – – V – – – – – – – – G
A/England/24/00 – – V – – – – – – – – –
Position 112 118 119 125 129 144 145 152 166 171 178
Consensus E R M E M L V E F I I
A/PR/8/34 A – – D I – I – L A V
A/Victoria/3/75 – – I D – – I – – – –
A/Sydney/97 – – – – – I – – – – –
A/England/492/95 – K – – I – – – – – –
A/England/41/96 – – – – I – – – – – –
A/England/919/99 – – – – – I – K – – –
A/England/24/00 – – – – – I – – – – –
Position 196 197 204 209 211 221 224 226 229 231-37
Consensus K N R N G K R A K
A/PR/8/34 E T – – R E G I E
A/Victoria/3/75 – T G – – – – – – RRDKMAD
A/Sydney/97 – – – S – – – – –
A/England/492/95 – – – – – – – – –
A/England/41/96 – – – – – – – – –
A/England/919/99 – – – – – E – – –
A/England/24/00 – – – – – E – – –
The NS1 protein from each virus is 230 amino acids long, with the exception of A/Victoria/3/75, which has an additional 7 amino acids at the carboxy terminus.
Fdash_, same amino acid as consensus.
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The extreme carboxy terminus from amino acid 215 onwards
binds PABII, and another region around amino acid 186
binds CPSF. On analysis of the sequences of the NS1
proteins in this study, we noted that the CPSF binding site
was totally conserved, whereas the PABII site differed. We
constructed a mutant of A/E/492/95 NS1 that lacked the
PABII site. This mutant efficiently blocked IFN-induced
ISRE gene expression (Fig. 9B).
NS1 localization in infected cells differs between A/PR/8/34
NS1 and NS1 of other influenza A viruses
We investigated the localization of the different NS1 proteins
during infection as this might influence their functional
properties. A549 cells were infected with wild-type viruses
and stained with anti-NS1 sera at 4, 6 and 8 h post-infection.
NS1 protein was not readily detectable at 2 h post-infection forany of the viruses (data not shown). By 6–8 h after infection,
the NS1 protein formed characteristic concentrated spots in the
nucleus of cells infected with A/Victoria/3/75 and A/Sydney/5/
97, indeed this formation was becoming apparent by 4 h in the
case of A/Sydney/5/97 (Fig. 10). In contrast, the concentrated
spots were not observed in the A/PR/8/34 infection, instead the
A/PR/8/34 NS1 appeared to be more evenly spread throughout
the cell, but clearly present both in the nucleus and cytoplasm at
4, 6 and 8 h post-infection. The NS1 protein during infection by
the recombinant virus containing A/PR/8/34 NS in a genetic
background of A/Victoria/3/75 showed a similar pattern to the
parental A/PR/8/34 virus.
Discussion
The ability of influenza A virus to block IFN-a/h induction
has been demonstrated to be a property of the NS1 protein
(Egorov et al., 1998; Garcia-Sastre et al., 1998; Noah et al.,
Fig. 5. Influenza A virus NS1 protein blocks induction of IFN-h promoter
activation. A549 cells (A) or Vero cells (B) were transfected with 0.67 Ag
pCAGG-NS1, 0.25 Ag h-galactosidase plasmid and 0.5 Ag IFN-h Luc
construct. 24 h post-transfection, cells were infected with Sendai Virus for 16
h (A) or transfected with dsRNA for 8 h (B). Luciferase activity was measured
and normalized to h-galactosidase activity for each transfection to account for
differences in translation and transfection efficiencies. (C) A Western blot was
performed to compare the amount of NS1 present in the A549 cell extracts,
using the SV5 tag for detection.
Fig. 6. Recombinant influenza A viruses that differ only in their segment
8 genes do not vary in their IFN-h induction in A549 cells. (A) The A549 IFN-
h Luc reporter cell line was infected with recombinant viruses containing
different NS genes in a stable genetic background (derived from A/Victoria/3/
75) at an moi of 5, and luciferase activity measured after 8 h. (B) A Western
blot was performed to compare the amount of NP and NS1 in infected cells at
8 h post-infection.
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proteins of a number of human influenza A viruses can inhibit
IFN-h induction to a similar extent in human alveolar
epithelial lung cells (A549) and Vero cells, irrespective of
the passage history of the viruses. The recombinant NS1
proteins derived from our panel of viruses could inhibit IFN-h
induction stimulated by Sendai Virus infection and dsRNA in
both cell types.Surprisingly, we discovered that certain strains, such as A/
Sydney/5/97 and two recent clinical isolates, induced IFN-h
following infection, even though their NS1 proteins could block
dsRNA induced IFN-h induction. We were able to rule out that
the high IFN-h induction byA/Sydney/5/97was explained by an
insufficient production of NS1 during infection. This implies
that other viral products of A/Sydney/5/97 can influence IFN-h
induction, and, furthermore, that the IFN-h induced by A/
Sydney/5/97 may be stimulated through a different mechanism
than the presence of dsRNA, since the A/Sydney/5/97 NS1
protein could efficiently block dsRNA signaling. It has recently
been shown that recombinant influenza viruses with the HA and
NA genes of A/Sydney/5/97 can induce TNFa production in
porcine lung epithelial cells (Seo et al., 2004), hence, it is
possible these gene segments may influence IFN-h induction in
a similar manner.
We also verified that IFN-h was synthesized and released
upon infection with our panel of viruses, as it has been
suggested that IFN-h might not be secreted from some cell
lines because the degree of apoptosis induced by virus infection
can prevent cytokines in the cytoplasm from being secreted
(Brydon et al., 2003). An ELISA confirmed that IFN-h was
present in the cell supernatants of infected cells, although the
levels of IFN-h that we measured were relatively low even for
our ‘‘strong’’ inducer A/Sydney/5/97 when compared with
Sendai virus which was selected here to induce a robust IFN
response.
Despite the IFN-h induced during A/Sydney/5/97 infection,
this virus was still able to undergo multi-cycle replication in
A549 cells, although progeny virus was not produced as rapidly
or to as high titers as A/PR/8/34 and A/Victoria/3/75. We
Fig. 7. Influenza A virus NS1 proteins block IFN-induced expression from an ISRE promoter and TNFainduced expression from a NF-nB promoter. (A) and (D)
A549 cells were transfected with 0.5 Ag ISRE Luc reporter construct. 24 h post-transfection, cells were infected with influenza A viruses at an moi of 5 for 16 h. 1000
IU IFN-a/ml was then applied for 6 h, and luciferase activity was measured in cell extracts. A549 cells (B) or Vero cells (C) were transfected with 0.67 Ag pCAGG-
NS1 and 0.25 Ag h-galactosidase reporter plasmid, together with 0.25 Ag ISRE Luc construct. 24 h post-transfection, cells were incubated with 1000 IU IFN-a/ml for
6 h. Luciferase activity was measured and normalized to h-galactosidase activity for each transfection.
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IFN-a on viral replication. Interestingly, we found that A/
Sydney/5/97 was less susceptible to the antiviral effects of IFN-
a than were either A/PR/8/34 or A/Victoria/3/75. Indeed, a small
fraction of the A/Sydney/5/97 stock (10%) was able to replicate
in cells treated with a higher IFN dose, 10,000 IU/ml IFN-a,
whereas A/PR/8/34 and A/Victoria/3/75 could not (data not
shown). Nevertheless, in contrast to the lethal Hong Kong 1997
H5N1 strains, A/Sydney/5/97 is not completely resistant to the
anti-viral effects of cytokines (Seo et al., 2002). It is also possible
that packaging defects in A/Sydney/5/97 could make this strain
contain resistant fractions (Marcus et al., 2005).
All of the NS1 proteins studied here, with the exception of A/
PR/8/34 NS1, blocked the expression of recently induced genes
either from an ISRE-containing promoter or from an NF-nB-
responsive promoter, and this effect was evident both in the
context of virus infection and when NS1 proteins were
exogenously expressed. The mechanism was not to inhibit
assembly of the transcription complex on the promoter DNA,
since this was clearly detected in the context of virus infectionwith a typical influenza virus, A/Victoria/3/75, as well as with A/
PR/8/34. These observations would support a post-transcrip-
tional mechanism for the inhibition of gene expression by NS1,
especially since the ability to block induced gene expression
mapped to the carboxy terminus of NS1 wherein lie binding sites
for CPSF and PABII.
It has previously been shown that expressed recombinant
A/PR/8/34 NS1 protein can enhance translation, possibly by
blocking PKR (Salvatore et al., 2002), and we also observed
that A/PR/8/34 NS1 enhanced its own translation (Fig. 4B)
and that of a co-expressed gene. Generally recombinant A/
PR8/34 NS1 enhanced h-galactosidase expression 3- to 4-fold.
It should be noted that this is taken into account in the relative
luciferase activity values shown in Figs. 5, 7, 8 and 9.
Although all of the other influenza A virus NS1 proteins could
inhibit IFN-h induction, none of them enhanced translation.
The mechanism of translational enhancement by A/PR/8/34
NS1 is not clear but seems unrelated to the mechanism by
which IFN-h induction is inhibited. Importantly, despite its
translational enhancement, A/PR/8/34 still blocked IFN-h
Fig. 8. Influenza viruses A/PR/8/34 and A/Victoria/3/75 do not block IFN-h or
TNFa signaling. (A) Cells were infected with virus at an moi of 5 for 4 h and
where indicated treated with IFN-a at 1000 IU/ml for a further 1 h before
preparing nuclear extracts. EMSAs were then carried out to detect ISGF3. (B)
A549 cells were transfected with 0.67 Ag pCAGG-NS1, 0.25 Ag h-
galactosidase reporter plasmid and 0.5 Ag NF-nB Luc reporter. 24 h post-
transfection, cells were incubated with 10 ng/ml of TNFa for 3 h, and luciferase
activity was measured and values were normalized. (C) Cells were infected as
described in panel A, and where indicated treated with 10 ng/ml of TNFa.
EMSAs were carried out to detect the presence of NF-nB in nuclear extracts.
Fig. 9. The effector domain of NS1 determines the ability of the NS1 protein
to block induction of an inducible promoter. (A) Vero cells were transfected
with wild-type PR8 and Victoria pCAGG-NS1 clones, chimeric NS1
constructs PR8:Vict and Vict:PR8 together with the ISRELuc and h-
galactosidase reporter constructs. Cells were subsequently incubated with
IFN-a, and lysates assayed for luciferase activity as described previously. (B)
A549 cells were transfected with wild-type PR8 or Eng/492/95 pCAGG-NS1
clones or a truncated Eng/492/95 pCAGG 215NS1 construct together with the
ISRELuc and h-galactosidase reporter constructs. Cells were subsequently
incubated with IFN-a, and lysates were assayed for luciferase activity as
described previously.
A. Hayman et al. / Virology 347 (2006) 52–6460promoter activation but did not inhibit induced gene expres-
sion relative to the controls. It therefore seems likely that this
virus does not have the ability to affect events downstream of
transcription in the same ways as do the other influenza A
virus NS1 proteins studied here. We are currently investigating
the genetic basis of this difference.There are 28-amino-acid differences between the A/PR/8/34
and A/Victoria/3/75 NS1 proteins, which might explain the
variations in their functional properties. Moreover, the amino
acid sequence of A/PR/8/34 is distinct from the other NS1
sequences in our panel of viruses. This is not surprising as A/PR/
8/34 is a considerably older strain. However, the positions which
have previously been shown as important for function remain
conserved, including positions 38 and 41 which are crucial for
dsRNA binding, and likewise the CPSF binding site (Noah et al.,
2003). Notably there are 2-amino-acid changes in the PABII
binding sites, and A/Victoria/3/75 has an additional 7 amino
acids at its carboxy terminal in comparison to A/PR/8/34; hence,
these changes may modulate the abilities of these proteins to
bind PABII. However, a truncated NS1 protein of 215 amino
acids, lacking the PABII binding site, did not lose the ability to
block the induction of the ISRE or NF-nB reporter genes (Fig.
9B). Finally, other changes might influence the functional
properties through determining the subcellular localization of
Fig. 10. Localization of NS1 in influenza A virus infected A549 cells. NS1 forms highly localized spots in the nucleus, with the exception of A/PR/8/34 NS1 which
localizes more evenly in the nucleus and cytoplasm. Cells were infected at an moi of 5 with wild-type virus or the A/PR/8/34 NS recombinant and stained 4, 6 and 8 h
post-infection with anti NS1 polyclonal sera and visualized with anti-rabbit FITC conjugate. (A) A/PR/8/34, (B) A/Victoria/3/75, (C) A/Sydney/5/97, (D) PR8/34 NS
recombinant in A/Victoria/3/75 and (E) mock.
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intracellular localization of NS1 we observed further supports
the idea that the A/PR/8/34 virus differs from other influenza
viruses in the activity of the NS1 protein. Previous reports have
shown NS1 to be present in either the nucleus, the cytoplasm or
both (Briedis et al., 1981; Falcon et al., 1999; Fortes et al., 1994;
Greenspan et al., 1988; Portela et al., 1985; Qian et al., 1994;
Talon et al., 2000). Presumably, this depends on the choice of
cell type, the time point of infection and whether the protein is
expressed as a recombinant protein. In addition, the protein
might associate with other host proteins sequestering it to a
particular part of the cell.
In the cell type (A549 cells) and time points (4–8 h post-
infection) we investigated, A/PR/8/34 NS1 (during infection
by both wild-type A/PR/8/34 and the recombinant derivative)
was spread evenly throughout the nucleus and cytoplasm,
whereas the other NS1 proteins moved to the nucleus where
they formed characteristic concentrated spots within 6 h of
infection. Thus, initially, when NS1 has first been synthesized
and is still present in the cytoplasm, it may dampen the
dsRNA induction of the IFN-h promoter. However, the
nuclear localization of some NS1 proteins 6 h post-infection
might enable interference with processing and export of newly
synthesized mRNA, as shown previously for the NS1 protein
derived from A/Udorn/72 (Qian et al., 1994), a strain which
shares strong sequence similarity to A/Victoria/3/75. Inagreement with this, Ortı´n and colleagues have also shown
that expressed AVictoria/3/75 NS1 formed concentrated spots
in the nucleus in COS-1 cells, and resulted in the accumulation
of nuclear mRNA (Falcon et al., 1999; Fortes et al., 1994;
Portela et al., 1985).
In summary, the mechanisms by which human influenza
A virus counters the IFN-a/h response are strain specific. It
is perhaps not surprising that the A/PR/8/34 virus which
may have been extensively adapted by passage through eggs
and mice over many years behaves differently to the other
strains. Our studies therefore highlight the importance of
bearing in mind the passage history and origin when
interpreting studies with viruses whose genes evolve rapidly
during interaction with a range of hosts.
Material and methods
Cells and viruses
293-T, MDCK, Vero and A549 cells were grown in 10%
Dulbecco’s modification of Eagle’s medium supplemented
with 10% fetal bovine serum, glutamine, pyruvate and
penicillin/streptomycin. An A549 cell line containing a stable
integrate of the firefly luciferase gene driven by the IFN-h
promoter (called IFN-hLuc) was maintained in the same
media supplemented with 2 mg/ml G418. Cells were
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obtained from the Health Protection Agency, Colindale,
London, UK, and were passaged a maximum of four times
in MDCK cells since recovery from nasal swabs (Thompson et
al., 2004). All virus strains were grown in MDCK cells in
medium without serum, containing 2 Ag/ml trypsin (Worthing-
ton). Influenza viruses were quantified by plaque assay on
MDCK cells as previously described (Elleman and Barclay,
2004). Sendai virus (SeV) vM3 was prepared in 10-day-old
embryonated hen’s eggs.
IFN-b induction luciferase assay
A549 cells stably containing the IFN-hLuc construct were
incubated with virus diluted in serum-free DMEM at a
multiplicity of infection (moi) of 5 pfu/cell in a 24-well plate
at 37 -C. After 1 h, the virus was replaced with 2%DMEM, and
the cells were incubated for a further 7 h. The cells were
washed once in PBS and then lysed in 50 Al CCLR buffer
(Promega) for 1 min. Cell debris was removed by centrifuga-
tion for 1 min at 13,000 rpm. 20 Al supernatant was added to
100 Al of Luciferase Substrate Reagent (Promega), and the
relative luciferase activity was measured on a Turner TD20/20
Luminometer according to the kit manufacturer’s instructions
(Promega).
To inactivate virus infectivity, virus inoculum was exposed
on ice at a distance of 10 cm to the ultraviolet radiation from a
germicidal lamp for 5 min. A hemagglutination assay was
performed with turkey red blood cells to ensure the virions
remained intact.
Measurement of IFN-b secretion by ELISA
A549 cells were infected as described above at an moi of 5
pfu/cell, in a 24-well plate. Sendai virus was used as a positive
control. 24 h post-infection, 100 Al of supernatant was directly
transferred to a well of an IFN-h ELISA 96-well plate (R&D
systems). The ELISA was performed according to the
manufacturer’s protocol, and the absorbance was measured at
450 nm. The amount of IFN-h was estimated, from the
standard curve.
Virus yield assay
A549 cells were incubated with or without 1000 IU/ml of
IFN-a (Intron A, Schering-Plough) for 24 h. The cells were
then infected at an moi of 0.01 and incubated in serum-free
DMEM with a final trypsin concentration of 0.1 Ag/ml. Fresh
trypsin was added daily. 48 h post-infection, cell culture
supernatants were harvested and titrated by plaque assay on
MDCK cells.
Generation of NS1 expression constructs
The pCAGG vector was adapted such that cloned genes
would be expressed as fusion proteins with a 14-amino-acid
long SV5 tag at their carboxy terminus. The new vector, termedpCAGGSV5, was engineered to contain MluI and NotI cloning
sites. NS1 was amplified from a full-length cDNA of segment
8 (the pol I NS clone, see below). PCR mutagenesis was used
to remove the splice acceptor sequence. PCR 1 included primer
pairs NS1NotIF 5V TATGCGGCCGCACAAAGACATAATG-
GAT 3V and SMAR 5V ATCCTCATCAGTATGCCCGGGAA-
GAGAAGGCAATGG3, which resulted in a ¨530-bp product.
PCR2 included primers SMAF 5V CCATTGCCTTCTCTTCC-
CGGGCATACTGATGAGGAT 3V and NS1MluIKR 5V AGC-
CATCTTATCACGCGTAACTTTTG 3V and gave a ¨200-bp
product. A different antisense primer, NS1MluIER, was used to
amplify A/PR/8/34 segment 8 RNA, to ensure the correct
sequence at amino acid position at 229 was incorporated (E
rather than a K). A third overlapping PCR3 was then performed
to amplify the full-length NS1, using the NS1NotIF and
NS1MluIKR or (NS1MluIER for A/PR/8/34), giving a 730-bp
product. The PCRs were performed using Bio-X-ACT short
(Bioline) according to the manufacturer’s instructions. The
product from PCR3 was then digested with NotI and MluI and
ligated into the pCAGGSV5 vector. Chimeric NS1 clones of A/
PR/8/34 and A/Victoria/3/75 were generated using the NcoI site
in the NS1pCAGGSV5 clones. Clone FPR8:Vict_ encodes the A/
PR/8/34 dsRNA-binding domain (amino acids 1–79) and A/
Victoria/3/75 effector domain (amino acids 80–237), whereas
clone Vict:PR8 contains the dsRNA-binding domain from A/
Victoria/3/75 (amino acids 1–79) and effector domain of A/PR/
8/34 (amino acids 80–230). A truncated clone A/E/492/95
pCAGG NS1, encoding the first 215 amino acids of the NS1
construct, was generated by PCR using forward primer
NS1NotF, and a reverse primer 215NS1 (5VAGCCGGTATTAC-
GCGTAGTAAGTG GAGGTCCCCCATTCTC 3V) with a MluI
site. The PCR product was then cloned into the pCAGGSV5
vector using the NotI and MluI sites as described previously.
Luciferase reporter gene assays
Three firefly luciferase reporter constructs were used
containing one of the following inducible promoters: (1)
IFN-hLuc containing IFN-h promoter, (2) ISRELuc:
contained 4 consecutive ISRE promoter elements, (3) NF-
nBLuc containing an NF-nB promoter. A DNA mix contain-
ing 0.25 Ag of the Luciferase reporter construct, 0.25 Ag h-
galactosidase plasmid pl and 0.67 Ag pCAGGSV5 NS1 or
empty vector were transfected into a 6-well plate of A549 s or
Vero cells using Polyfect (Qiagen) or Lipofectamine 2000
(LF2000, Invitrogen) according to the manufacturer’s instruc-
tions. 24 h post-transfection, the reporter genes were induced
depending on the construct. The IFN-hLuc reporter construct
was induced by transfection with dsRNA for 8 h or infection
with a high moi of SeV for 16 h. The ISRELuc construct was
induced by treatment with 2000 IU/well of IFN-a for 6 h.
The NF-nB promoter was induced by incubation with 20 ng/
well of TNFa (R&D Systems) for 3 h. After the induction
time had elapsed, cells were lysed in 200 Al CCLR buffer
(Promega). h-Galactosidase activity was measured, and the
relative luciferase activity was normalized accordingly.
Extracts were prepared in RIPA buffer in parallel for Western
A. Hayman et al. / Virology 347 (2006) 52–64 63blot analysis to determine the amount of NS1 protein made
by each construct. A/PR/8/34 NS1 clones with and without
the SV5 epitope tag were tested in the IFN-hLuc reporter
assay to confirm that the tag did not effect the function of the
protein in these assays.
Western blot analysis
A mouse anti SV5 tag antibody (Immunologicals Direct)
was used for detection of the SV5 tagged NS1 proteins. Mouse
anti-NP antibody (Immunologicals Direct) and anti-NS1 serum
(kindly provided by Dr. P Digard, University of Cambridge)
were used for detection in virus infected cells. The anti-SV5
and NP antibodies were diluted 1:1000 in 4% dried skimmed
powder milk, PBS with 0.1% Tween-20. The anti-NS1 serum
was diluted 1:500 in 4% dried skimmed powder milk, 5%
horse serum, in PBS with 0.1% Tween-20. Bound antibodies
were detected with HRP-labeled secondary antibodies.
Generation of recombinant viruses
vRNAwas extracted from 140 Al of viral supernatant (of the
virus stocks generated in MDCKs as described above) using a
QIAmp Viral RNA mini kit (Qiagen) according to the
manufacturers instructions. cDNA was synthesized from 5 to
10 Al RNA, using AMV reverse transcriptase (Promega) and 50
pmol of a primer complementary to the first 12 nucleotides of the
3Vends of all 8 of the vRNA segments. The NS gene was PCR
amplified from the cDNA using specific sense and antisense
primers complementary to the 3V and 5V end of segment
8 respectively which contained BsmBI sites to enable cloning
into the pPolIRT vector (originally obtained from Dr. T Zurcher,
GlaxoSmithKline). A proof reading enzyme, Bio-X-ACT short
(Bioline), was used according to the manufacturer’s protocol.
The PCR product was digested with BsmBI and cloned into the
pPol IRT vector. The NS pol I clones were combined with the
remaining 7 plasmids with cDNAs based on an influenza A/
Victoria/3/75 virus genetic background. Recombinant viruses
were rescued by 12 plasmid transfection into 293-T cells and co-
cultivation with MDCK cells, as described previously (Thomp-
son et al., 2004). The rescued viruses were plaque purified, and
stocks were grown in MDCK cells. The stocks were
subsequently titrated on MDCK cells, and the NS gene
sequenced to confirm the correct origin of the segment and
that no mutations had arisen.
Immunofluorescence
IRF-3
A549 cells were infected at an moi of 5 for 8 h. Cells were
fixed and permeabilized in 4% paraformaldehyde and 0.2%
Triton PBS respectively. Cells were incubated with rabbit anti-
IRF-3 antibody (FL-425, Santa Cruz) and mouse anti-influenza
A NP antibody (Immunologicals Direct) for 1 h. After three
washes in PBS, cells were incubated with an anti-rabbit FITC-
labeled secondary and anti-mouse Texas Red-labeled second-
ary respectively for 1 h.NS1
A549 cells were infected at an moi of 5 for 8 h. Cells were
fixed and permeabilized in ice-cold methanol:acetone (1:1) for
10 min and washed in PBS before blocking overnight in PBS
containing 5% horse serum and 3% BSA at room temperature.
Rabbit anti-NS1 sera were diluted 1:200 in blocking buffer and
applied to the cells for 3 h. After three washes, a goat anti-
rabbit FITC-labeled secondary antibody (Immunological di-
rect) diluted 1:200 was added for 1 h. Slides were then
mounted in Vectashield.
EMSAs
Nuclear extracts were prepared from confluent 9-cm dishes
of A549 cells as previously described (Whiteside et al., 1992).
Where indicated, cells were infected with virus at an moi of 5
for 4 h and then treated with IFN-a at 1000 IU/ml or TNFa at
10 ng/ml for a further hour before harvesting for extraction.
EMSAs were then carried out for either NF-nB (Visvanathan
and Goodbourn, 1989) or ISGF3 (Didcock et al., 1999b) as
previously described.
RNAse protection assays
Confluent 9-cm dishes of A549 cells were infected with virus
at an moi of 5. Two hours post-infection, cells were treated for a
further 2 h with IFN-a 1000 u/ml. RNAwas prepared using an
RNeasy mini kit (Qiagen). 10 Ag of RNA was used for each
hybridization reaction. Conditions and probes for detection of
human IFN-h, human g-actin and 6–16 (ISG56) have been
previously described (King and Goodbourn, 1994).
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